Evommune (EVMN) Assets (2024 - 2026)

Name: Evommune (EVMN) Assets (2024 - 2026) | Business Quant
Creator: Business Quant

Evommune (EVMN) reported Assets of $322.5 million for Q1 2026, up 43.35% on a QoQ basis from $224.9 million in Q4 2025.

Evommune (EVMN) has 3 years of Assets data on file, last reported at $322.5 million in Q1 2026.

Quarterly Assets changed N/A year-over-year to $322.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $322.5 million (changed N/A YoY) and the FY2025 annual result came in at $224.9 million, up 195.77% from the prior year.
Assets improved to $322.5 million in Q1 2026 per EVMN's latest filing, from $224.9 million in the prior quarter.
Across five years, Assets topped out at $322.5 million in Q1 2026 and bottomed at $76.1 million in Q4 2024.
The 3-year median for Assets is $154.7 million (2025), against an average of $177.0 million.
Peak annual rise in Assets reached 195.77% in 2025, while the deepest fall reached 195.77% in 2025.
Tracing EVMN's Assets over 3 years: stood at $76.1 million in 2024, then jumped by 195.77% to $224.9 million in 2025, then soared by 43.35% to $322.5 million in 2026.
Per Business Quant, the three latest EVMN Assets figures stand at $322.5 million (Q1 2026), $224.9 million (Q4 2025), and $84.5 million (Q3 2025).

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	14.93 Mn
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	37.37 Mn
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	1.73 Bn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	78.88 Mn
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	33.89 Mn
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	26.48 Bn
7	Evaxion A	62.56 Bn	62.54 Bn	-	23.64 Mn
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	40.87 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	5.13 Bn
10	Evommune	744.11 Mn	532.65 Mn	-	322.46 Mn

Download Data 🔒